Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.7 |
mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.024 | 0.7 |
mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.7 |
mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.023 | 0.7 |